1 Duke Clinical Research Institute, Durham, NC.
2 Department of Pediatrics, Duke University, Durham, NC.
3 Department of Surgery, Duke University, Durham, NC.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/pccmjournal).
Supported, in part, by the National Institute of General Medical Sciences T32 University of North Carolina-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program (5T32GM086330-08) and the National, Heart, Lung, and Blood Institute R25 Bridging the Gap to Enhance Clinical Research Program (5R25HL135304-04).
Drs. Kumar’s and Flair’s institutions received funding from the National Institute of General Medical Sciences T32 University of North Carolina-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program (5T32GM086330-08) and the National Heart, Lung, and Blood Institute R25 Bridging the Gap to Enhance Clinical Research Program (5R25HL135304-04). Drs. Kumar, Flair, and Zimmerman received support for article research from the National Institutes of Health (NIH). Dr. Zimmerman’s institution received funding from Biogen Foundation; she received funding from the NIH and Purdue Pharma; she disclosed the off-label product use of digoxin in infants with single-ventricle congenital heart disease. The remaining authors have disclosed that they do not have any potential conflicts of interest.
For information regarding this article, E-mail: [email protected]
